News
Recipharm invests in fill finish capacity
Global contract development and manufacturing organisation (CDMO), Recipharm, has announced investment into a new facility in Uttarakhand, India which will see its fill finish capacity increase to 1 billion sterile units per year.
The facility will be constructed on a...
News
Vibalogics advances growth with key global commercial leadership hires
Vibalogics, a global contract development and manufacturing organization (CDMO) specializing in the production of oncolytic viruses, viral vectors, and vaccine virotherapy products, has announced the appointment of key senior U.S.-based hires to the global leadership team.
Dr. Roger Lias joins...
News
Ashfield launches Cell & Gene Therapy Commercialization Network, EmerGENE
Ashfield, part of UDG Healthcare plc, has announced the launch of EmerGENE, a global end-to-end cell and gene therapy network approach which promises to support small and midsize biotechs with the commercialization of their discoveries.
The first of its kind...
News
Senegal and Team Europe agree to build a manufacturing plant to produce vaccines against COVID-19 and other endemic diseases
Producing COVID-19 vaccines in Africa came one step closer today after Team Europe formally agreed to support large-scale investment in vaccine production by the Institut Pasteur in Dakar, alongside other support measures. The new manufacturing plant should reduce Africa's...
News
Serum Institute partners with RDIF to make 300 mn doses of Sputnik V
Sputnik V’s production in India has received a shot in the arm as the developers of the Russian Covid-19 vaccine and Serum Institute of India (SII) announced a partnership agreement on Tuesday to manufacture more than 300 million doses,...
News
Sri Trang Group accelerates Covid inoculation program
Pressing ahead with its campaign to provide inoculation to all Southeast Asia based employees of the Sri Trang Group of Companies against Covid-19 with Sinopharm vaccine, provided by the Chulabhorn Royal Academy, Sri Trang Gloves (Thailand) PCL reached its...
Clinical Trials
Genoskin launches the ISR platform: the first human skin ex vivo platform to study injection site reactions ahead of clinical trials
Genoskin announces the launch of the ISR platform®, a new pre-clinical toolbox designed to study injection site reactions (ISR) in humans ahead of clinical trials. The company has filed intellectual property to protect its transformative platform worldwide. With the...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















